In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eating Our Seed Corn

Executive Summary

The drug industry's preoccupation with late-stage products means they're largely ignoring early-stage companies. But unlike earlier years, these biotechs have no financing alternative: the stock market now marches in lockstep with Big Pharma trends. But as the extraordinary valuations of the large biotechs shows, the early-stage companies of today can be the late-stage companies of tomorrow--and the source of Big Pharma's late-stage product opportunities. If drug firms don't act now to encourage early-stage investment--either through lobbying for governmental investment incentives or through their own venture investing--they may, in focusing so exclusively on late-stage deals, be eating their own seed corn.

You may also be interested in...



December ANDA Rush Is Largest In Two Years

December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.

Korean Pharma Highlights R&D Progress, 2020 Strategy At JPM

Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.

Buckle Up, Industry: EWG Finds ‘4 Million Asbestos Fiber Structures’ In Makeup For Young Girls

US House Energy and Commerce Chair Frank Pallone took note on 16 January of the Environmental Working Group’s finding of asbestos contamination in a “Princess” makeup set intended for young girls. Rep. Debbie Dingell, D-MI, will speak to the test results first, pushing her own legislation that would require asbestos testing of talc-containing children’s cosmetics in accordance with preferred methods.

Topics

Related Companies

UsernamePublicRestriction

Register

IV001258

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel